← Back to headlines
Roivant Sciences Stock Surges on Positive Trial Results for Mosliciguat
Shares of Roivant Sciences jumped 19% after the company reported positive clinical trial results for its drug candidate mosliciguat.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
